BioCardia to Participate in Cantor Fitzgerald’s Cell and Genetic Medicines Conference
BioCardia, Inc. [Nasdaq: BCDA] will present at Cantor Fitzgerald’s Cell and Genetic Medicines Conference on September 15, 2022, held at the Lotte New York Palace Hotel, NYC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia, Inc. [Nasdaq: BCDA] will present at Cantor Fitzgerald’s Cell and Genetic Medicines Conference on September 15, 2022, held at the Lotte New York Palace Hotel, NYC. The conference will focus on advancements in cell therapies, including CRISPR technologies and regulatory pathways. CEO Dr. Peter Altman will join a panel discussing the significance of partnerships with large-cap pharma. Attendance is in person only, with no live broadcast. BioCardia specializes in cell-based therapeutics for cardiovascular diseases, with its CardiAMP therapies receiving FDA Breakthrough designation and CMS reimbursement.
Details
News Market Reaction – BCDA
The recorded move for BCDA in the trading session of this news was +2.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced it will participate on a panel as a presenting company at Cantor Fitzgerald’s Cell and Genetic Medicines Conference. The conference is being held in person on September 15, 2022, at the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue.
The conference will feature insightful panel presentations covering key topics and themes spanning the expansion of cell therapies; AAV and lentiviral-based gene therapies; emergence of CRISPR technologies; discussions on regulatory pathways, manufacturing, and clinical development; and highlights of key commercial considerations as more therapies near the finish line.
Dr. Peter Altman, CEO of BioCardia, will participate in the morning panel session titled: “Ring Ring: Is That Large-Cap Pharma Calling? Importance of Established Partnerships in Place.”
Cantor Fitzgerald is not broadcasting the event; it is for in-person attendance only.
Event: Cantor Fitzgerald’s Cell and Genetic Medicines Conference
Date: September 15, 2022
Location: Lotte New York Palace Hotel, New York, NY.
About BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and NK1R+ allogeneic cell therapies are the Company’s biotherapeutic platforms that enable four product candidates in development. The CardiAMP Cell Therapy Heart Failure Trial investigational product has been granted Breakthrough designation by the FDA, has CMS reimbursement, and is supported financially by the Maryland Stem Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial also has CMS Reimbursement. BioCardia also partners with other biotherapeutic companies to provide its delivery systems. For more information visit: www.BioCardia.com.
Media Contact:
Anne Laluc, Marketing
Email: alaluc@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.